U.S. markets close in 3 hours 49 minutes

Caribou Biosciences, Inc. (CRBU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.09-0.55 (-6.37%)
As of 12:11PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.64
Bid8.20 x 1000
Ask8.23 x 800
Day's Range8.05 - 9.06
52 Week Range6.41 - 32.65
Avg. Volume677,722
Market Cap491.107M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.64
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.43
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CRBU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Caribou Biosciences, Inc.
    Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    Fair Value
    Economic Moat
    10 days agoMorningstar
View more
  • GlobeNewswire

    Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells

    -- Data presented at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) --BERKELEY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of studies in primary human T cells highlighting the mechanism underlying the superior specificity of the company’s CRISPR hybrid RNA-DNA (chRDNA) guides for genome editing. “Our chRDNA guides pr

  • Benzinga

    Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study

    Caribou Biosciences Inc (NASDAQ: CRBU) announced initial data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). These initial data will be shared at the European Hematology Association (EHA) 2022 Hybrid Congress. The EHA abstract includes safety, tolerability, and initial antitumor activity of CB-010 administered at dose level 1 (40x106 CAR-T cells) to 6 patients with r/r B-NHL who had relapsed after previous treatment. As of the February

  • GlobeNewswire

    Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy

    Patient response rates following treatment with CB-010, single dose at dose level 1, in the ANTLER Phase 1 trial Footnote: data cutoff date of February 23, 2022, data collection ongoing, efficacy based on Lugano criteria -- 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) achieved following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- -- CB-010 is the 1st allogeneic CAR-T cell therapy to achieve 100% ORR (5 of 5 patients) -- -- Based on promising initial safet